Evidence map›Paper›PMID 24293258›Full record

ArticleInternational journal of hematology2014

Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Weiyi Xu, Baode Chen, Xiangmin Tong

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Emergence ofJournal of hematology · 2020
    Article
  4. Article
  5. Article
  6. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
    Article
  7. Acute Lymphoblastic Leukemia in the Course of Polycythemia Vera: A Case Report and Review of Literature.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2016
    Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Weiyi XuDepartment of Clinical Laboratory, The First Affiliated Hospital, School of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, China, xz1717@aliyun.com.
Baode Chen
Xiangmin Tong

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The JAK2 V617F mutation is common in patients with Philadelphia-negative chronic myeloproliferative neoplasms, but few cases of the JAK2 V617F mutation have been described in Philadelphia-positive chronic myeloid leukemia (CML) patients. Here, we report a 21-year-old female who presented with phenotype of CML in whom BCR-ABL transcript and JAK2V617F mutation co-occurred. These findings were determined through cytogenetic analysis, fluorescence in situ hybridization, and allele-specific (AS) PCR. The patient's BCR-ABL transcript disappeared after 6 months of treatment with imatinib, while the JAK2V617F mutation remained positive. We discuss this case with reference to the current literature.

Indexed as

MutationChromosome BandingDNA Mutational AnalysisFemaleFusion Proteins, bcr-ablHumansIn Situ Hybridization, FluorescenceJanus Kinase 2Leukemia, Myelogenous, Chronic, BCR-ABL PositiveTreatment OutcomeYoung AdultFusion Proteins, bcr-ablJanus Kinase 2

Identifiers

PMID24293258

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.